ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

CUE vs DERM // 10Y YIELD & FRED MACRO BETA

Cue Biopharma Inc. (NASDAQ) VS. Journey Medical Corporation (NASDAQ) • 15-METRIC TALLY: CUE 3 — DERM 5
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CUE VS. DERM) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC CUE DERM SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 65.80% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -19.50% -15.50 DERM /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -14.03% -8.15% -5.88 DERM /fcf-yield <GO>
Operating Margin -60.00% -13.30% -46.70 DERM /operating-margins <GO>
Net Profit Margin -60.00% -18.70% -41.30 DERM /net-margins <GO>
Revenue Growth (YoY) 180.00% 11.10% +168.90 CUE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 0.74 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 5/9 -1.00 DERM /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 46.7 40.5 +6.24 CUE /rsi-technicals <GO>
10Y Yield & FRED Macro Beta ACTIVE — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $155.8M $152.7M $3.1M CUE /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR CUE REV DERM REV CUE GROSS % DERM GROSS % CUE FCF DERM FCF
FY 2025 $27.5M $61.2M — 65.8% -$21.9M -$12.4M
FY 2024 $9.3M $55.1M — 62.1% -$36.4M -$9.1M
FY 2023 $5.5M $59.7M — — -$40.0M $5.2M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CUE // BETA —
DERM // BETA —